PMID- 17767012
OWN - NLM
STAT- MEDLINE
DCOM- 20080107
LR  - 20070903
IS  - 1735-1383 (Print)
IS  - 1735-1383 (Linking)
VI  - 4
IP  - 3
DP  - 2007 Sep
TI  - Dendritic cells and their role in cancer immunotherapy.
PG  - 127-44
AB  - Dendritic cells (DCs) are antigen presenting cells with unique capability to take 
      up and process antigens in the peripheral blood and tissues. They subsequently 
      migrate to draining lymph nodes where they present these antigens and stimulate 
      naive T lymphocytes. During their life cycle, DCs go through two maturation 
      stages and are referred to as immature and mature cells, respectively. While 
      immature DCs are very good at capturing antigens, mature DCs are suitably 
      equipped to present antigens to T cells and to initiate an immune response. DCs 
      with different phenotypes serve as sentinels in nearly all tissues including the 
      peripheral blood, where they are continuously exposed to antigens. Very small 
      numbers of activated DCs are extremely efficient at generating immune response 
      against viruses, other pathogens and in experimental models of tumors. Protection 
      against infectious microorganisms and probably against tumors is provided by 
      complex interactions of the innate and adaptive immune systems. For the 
      initiation to occur, pathogens must first be recognized as a "danger". DC 
      possesses specific receptors to detect such danger signals. The unique 
      immune-stimulating properties of DC and the feasibility of manipulating their 
      function arouse much enthusiasm and hold great promise for the treatment of 
      cancer. Early clinical trials showed that DC can induce immune responses in 
      cancer patients. Nonetheless, cancer treatments based on DC administration 
      require further studies that will optimize this promising treatment modality.
FAU - Jalili, Ahmad
AU  - Jalili A
AD  - Division of Immunology, Allergy and Infectious Diseases, Department of 
      Dermatology, Medical University of Vienna, Vienna, Austria. 
      ahmad.jalili@meduniwien.ac.at
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Iran
TA  - Iran J Immunol
JT  - Iranian journal of immunology : IJI
JID - 101282932
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antigens, Surface)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, CD/immunology/metabolism
MH  - Antigens, Neoplasm/immunology
MH  - Antigens, Surface/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cytokines/immunology/*metabolism
MH  - Dendritic Cells/*immunology/physiology
MH  - Humans
MH  - *Immunotherapy
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/*immunology
RF  - 213
EDAT- 2007/09/04 09:00
MHDA- 2008/01/08 09:00
CRDT- 2007/09/04 09:00
PHST- 2007/09/04 09:00 [pubmed]
PHST- 2008/01/08 09:00 [medline]
PHST- 2007/09/04 09:00 [entrez]
AID - 01 [pii]
PST - ppublish
SO  - Iran J Immunol. 2007 Sep;4(3):127-44.